Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL
NCT06499870Phase 2Recruiting
- Sponsor
- Sean Sachdev
- Start
- Sep 2024
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tissue-plasminogen activator and enzalutamide in prostate adenocarcinoma, sponsored by Sean Sachdev. Primary endpoint: Pathologic response (biopsy positivity rate) at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
tissue-plasminogen activatorenzalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06499870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499870.